688356 键凯科技
已收盘 07-30 15:00:00
资讯
新帖
简况
键凯科技:下游客户中包括部分小核酸药物的研发企业
格隆汇资讯 · 08:55
键凯科技:下游客户中包括部分小核酸药物的研发企业
键凯科技:关于伊立替康项目Ⅲ期临床进度及合作情况
证券之星 · 08:51
键凯科技:关于伊立替康项目Ⅲ期临床进度及合作情况
键凯科技:受试者遵循方案完成4次给药治疗故无4次以上的用药
证券之星 · 08:51
键凯科技:受试者遵循方案完成4次给药治疗故无4次以上的用药
键凯科技:与康希诺合作开发新型可离子化甾醇脂质递送系统
证券之星 · 08:51
键凯科技:与康希诺合作开发新型可离子化甾醇脂质递送系统
肿瘤治疗概念盘中拉升,键凯科技涨12.91%
市场透视 · 07-24
肿瘤治疗概念盘中拉升,键凯科技涨12.91%
A股创新药概念延续强势,亚宝药业涨停,键凯科技、汉商集团、悦康药业、哈三联、海特生物等涨幅居前
华尔街见闻 · 07-24
A股创新药概念延续强势,亚宝药业涨停,键凯科技、汉商集团、悦康药业、哈三联、海特生物等涨幅居前
键凯科技:创新药伊立替康有三个临床试验适应症
证券之星 · 07-22
键凯科技:创新药伊立替康有三个临床试验适应症
7月21日键凯科技(688356)龙虎榜数据:机构净买入3914.54万元
证券之星 · 07-21
7月21日键凯科技(688356)龙虎榜数据:机构净买入3914.54万元
键凯科技涨5%创近1年新高
智选洞察 · 07-21
键凯科技涨5%创近1年新高
键凯科技获融资买入0.48亿元,近三日累计买入0.89亿元
金融界 · 07-19
键凯科技获融资买入0.48亿元,近三日累计买入0.89亿元
7月18日键凯科技涨11.95%,金信价值精选混合A基金重仓该股
证券之星 · 07-18
7月18日键凯科技涨11.95%,金信价值精选混合A基金重仓该股
键凯科技:凝胶项目已取得生产许可证
证券之星 · 07-16
键凯科技:凝胶项目已取得生产许可证
键凯科技:mRNA肿瘤疫苗处于临床前研究阶段
证券之星 · 07-16
键凯科技:mRNA肿瘤疫苗处于临床前研究阶段
键凯科技:水光针项目目前处于CMDE技术审评阶段
证券之星 · 07-16
键凯科技:水光针项目目前处于CMDE技术审评阶段
肿瘤治疗概念盘中拉升,广生堂涨6.94%
市场透视 · 07-16
肿瘤治疗概念盘中拉升,广生堂涨6.94%
每周股票复盘:XD键凯科(688356)键凯科技2024年年度权益分派实施
证券之星 · 07-12
每周股票复盘:XD键凯科(688356)键凯科技2024年年度权益分派实施
键凯科技:公司在小核酸药物方面有部分自研管线
证券之星 · 07-02
键凯科技:公司在小核酸药物方面有部分自研管线
键凯科技:丝玫瑰产品使用新型PEG衍生物作为交联剂
证券之星 · 07-02
键凯科技:丝玫瑰产品使用新型PEG衍生物作为交联剂
中国创新药能否持续让世界买单?券商分析师最新观点
券商中国 · 06-30
中国创新药能否持续让世界买单?券商分析师最新观点
键凯科技06月26日遭主力抛售211.9万元
市场透视 · 06-26
键凯科技06月26日遭主力抛售211.9万元
加载更多
公司概况
公司名称:
北京键凯科技股份有限公司
所属行业:
化学原料和化学制品制造业
上市日期:
2020-08-26
主营业务:
北京键凯科技股份有限公司的主营业务是医用药用聚乙二醇及其活性衍生物的研发、生产和销售。公司的主要产品是医用药用聚乙二醇及其活性衍生物。国家级专精特新“小巨人”企业、制造业“单项冠军”。
发行价格:
41.18
{"stockData":{"symbol":"688356","market":"SH","secType":"STK","nameCN":"键凯科技","latestPrice":97.28,"timestamp":1753858800000,"preClose":102.03,"halted":0,"volume":2173681,"delay":0,"changeRate":-0.0466,"floatShares":60650700,"shares":60650700,"eps":0.4496,"marketStatus":"已收盘","change":-4.75,"latestTime":"07-30 15:00:00","open":100,"high":101.99,"low":96.26,"amount":215000000,"amplitude":0.0562,"askPrice":97.28,"askSize":6,"bidPrice":97.25,"bidSize":7,"shortable":0,"etf":0,"ttmEps":0.4496,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753925400000},"marketStatusCode":5,"adr":0,"adjPreClose":102.03,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753839000000,1753846200000],[1753851600000,1753858800000]],"highLimit":112.23,"lowLimit":91.83,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":60650700,"isCdr":false,"pbRate":4.61,"roa":"--","peRate":216.370107,"roe":"0.93%","epsLYR":0.49,"committee":-0.6,"marketValue":5900000000,"turnoverRate":0.0358,"status":1,"afterMarket":{"amount":0,"volume":0,"close":97.28,"buyVolume":0,"sellVolume":0,"time":1753860838019,"indexStatus":"已收盘 07-30 15:30:00","preClose":102.03},"floatMarketCap":5900000000},"requestUrl":"/m/hq/s/688356","defaultTab":"news","newsList":[{"id":"2555043847","title":"键凯科技:下游客户中包括部分小核酸药物的研发企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2555043847","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555043847?lang=zh_cn&edition=full","pubTime":"2025-07-30 16:55","pubTimestamp":1753865709,"startTime":"0","endTime":"0","summary":"格隆汇7月30日丨键凯科技(688356.SH)在投资者互动平台表示,公司与康希诺生物子公司康希诺(上海)生物研发有限公司合作开发的基于新型可离子化甾醇脂质(ISL)的三组分脂质纳米颗粒(ISL-3C-LNP)递送系统在安全性提高和细胞免疫应答增强方面有显著效果,并具有组分简化与专利优势,相关研究已发表在国际权威期刊ACS Applied Materials & Interfaces上。公司下游客户中包括部分小核酸药物的研发企业,公司基于客户需求为客户提供各类常规或定制化产品。目前公司客户均处在临床前或早期临床阶段,尚未对公司营业收入产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730165529972768b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730165529972768b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688356","BK0229"],"gpt_icon":0},{"id":"2555019929","title":"键凯科技:关于伊立替康项目Ⅲ期临床进度及合作情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2555019929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555019929?lang=zh_cn&edition=full","pubTime":"2025-07-30 16:51","pubTimestamp":1753865487,"startTime":"0","endTime":"0","summary":"证券之星消息,键凯科技07月30日在投资者关系平台上答复投资者关心的问题。关于伊立替康项目,原有意向方及一些新进的意向方都在继续关注伊立替康项目Ⅲ期临床的进度,不排除随着三期临床的开展,可能会有新的合作伙伴加入进来的可能性。具体后续进展情况请您以公司官方披露为准。感谢您的建议,再次感谢您对键凯科技的关注!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073000026785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688356","BK0229"],"gpt_icon":0},{"id":"2555019921","title":"键凯科技:受试者遵循方案完成4次给药治疗故无4次以上的用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2555019921","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555019921?lang=zh_cn&edition=full","pubTime":"2025-07-30 16:51","pubTimestamp":1753865487,"startTime":"0","endTime":"0","summary":"证券之星消息,键凯科技07月30日在投资者关系平台上答复投资者关心的问题。研究中受试者遵循方案完成4次给药治疗故无4次以上的用药,其中部分受试者因疾病仅完成3次给药。在最多4个周期注射用聚乙二醇伊立替康治疗下使受试者的中位生存期延长至12.1个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073000026786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688356","BK0229"],"gpt_icon":0},{"id":"2555019923","title":"键凯科技:与康希诺合作开发新型可离子化甾醇脂质递送系统","url":"https://stock-news.laohu8.com/highlight/detail?id=2555019923","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555019923?lang=zh_cn&edition=full","pubTime":"2025-07-30 16:51","pubTimestamp":1753865486,"startTime":"0","endTime":"0","summary":"证券之星消息,键凯科技07月30日在投资者关系平台上答复投资者关心的问题。公司与康希诺生物子公司康希诺(上海)生物研发有限公司合作开发的基于新型可离子化甾醇脂质的三组分脂质纳米颗粒递送系统在安全性提高和细胞免疫应答增强方面有显著效果,并具有组分简化与专利优势,相关研究已发表在国际权威期刊ACSAppliedMaterials&Interfaces上。再次感谢您对键凯科技的关注!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073000026784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688356","688185","BK0229"],"gpt_icon":0},{"id":"2553227537","title":"肿瘤治疗概念盘中拉升,键凯科技涨12.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553227537","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553227537?lang=zh_cn&edition=full","pubTime":"2025-07-24 09:47","pubTimestamp":1753321645,"startTime":"0","endTime":"0","summary":"07月24日,肿瘤治疗概念盘中拉升,截至09点47分,肿瘤治疗概念整体指数上涨1.03%,报1676.640点。从个股上来看,该概念的成分股中,键凯科技涨12.91%,沃森生物、迪哲医药-U2只股涨幅超过5%。从资金上来看,截止发稿,肿瘤治疗概念主力净流入为-1.77亿,其中恒瑞医药受到资金热捧,主力净流入4686.57万;拉长时间线来看,该板块近20日主力资金净流入-39.86亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724094725971aef26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724094725971aef26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688356","BK0229","688192"],"gpt_icon":0},{"id":"2553222660","title":"A股创新药概念延续强势,亚宝药业涨停,键凯科技、汉商集团、悦康药业、哈三联、海特生物等涨幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2553222660","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553222660?lang=zh_cn&edition=full","pubTime":"2025-07-24 09:35","pubTimestamp":1753320947,"startTime":"0","endTime":"0","summary":"A股 创新药 概念延续强势, 亚宝药业 涨停, 键凯科技 、 汉商集团 、 悦康药业 、 哈三联 、 海特生物 等涨幅居前。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724095832a6be9229&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724095832a6be9229&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159982","BK0201","300683","159992","688356","BK0077","002900","600351","BK0096","BK0209","BK0229","BK0028","688658","600774","399300","BK0239"],"gpt_icon":0},{"id":"2553280527","title":"键凯科技:创新药伊立替康有三个临床试验适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2553280527","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553280527?lang=zh_cn&edition=full","pubTime":"2025-07-22 15:37","pubTimestamp":1753169828,"startTime":"0","endTime":"0","summary":"证券之星消息,键凯科技07月22日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司在创新药领域,是否布局了10多个管线?包含一个临床三期?目前公司的创新药项目伊立替康有三个处于临床试验的适应症:小细胞肺癌适应症处于Ⅲ期临床试验,伴脑转移的乳腺癌适应症和脑胶质瘤适应症处于Ⅱ期临床试验。再次感谢您对键凯科技的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072200019903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","06978","BK0229","BK1583","BK1576","BK1141","159992","688356","03347","BK1161"],"gpt_icon":0},{"id":"2553247839","title":"7月21日键凯科技(688356)龙虎榜数据:机构净买入3914.54万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553247839","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553247839?lang=zh_cn&edition=full","pubTime":"2025-07-21 17:42","pubTimestamp":1753090960,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2025年7月21日公布的交易公开信息显示,键凯科技因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券,有价格涨跌幅限制的连续3个交易日内收盘价格涨幅偏离值累计达到30%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年7月21日收盘,键凯科技报收于110.16元,上涨20.0%,涨停,换手率7.96%,成交量4.83万手,成交额4.87亿元。从龙虎榜公布的当日买卖数据来看,机构合计净买入3914.54万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072100024499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688356","BK0229"],"gpt_icon":0},{"id":"2553447272","title":"键凯科技涨5%创近1年新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2553447272","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553447272?lang=zh_cn&edition=full","pubTime":"2025-07-21 09:30","pubTimestamp":1753061440,"startTime":"0","endTime":"0","summary":"07月21日,键凯科技股价大幅上涨,截至09点30分,键凯科技上涨5.12%,报96.50元/股,创近1年新高,成交2765万元,换手率0.48%,振幅2.02%。资金动向截止发稿,键凯科技获得主力净流入328万元,其中超大单流入411万元,大单流出82万元。最新财报显示,今年一季报,键凯科技实现营业收入6,910.41万元,同比增长6.66%,净利润为1,188.05万元,同比减少17.79%,基本每股收益为0.20元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721093211a6b6790d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721093211a6b6790d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0229","688356"],"gpt_icon":0},{"id":"2552154413","title":"键凯科技获融资买入0.48亿元,近三日累计买入0.89亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552154413","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552154413?lang=zh_cn&edition=full","pubTime":"2025-07-19 08:02","pubTimestamp":1752883350,"startTime":"0","endTime":"0","summary":"7月18日,沪深两融数据显示,键凯科技获融资买入额0.48亿元,居两市第365位,当日融资偿还额0.48亿元,净卖出82.32万元。最近三个交易日,16日-18日,键凯科技分别获融资买入0.21亿元、0.21亿元、0.48亿元。融券方面,当日融券卖出0.00万股,净卖出0.00万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071908160497abaedd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071908160497abaedd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0229","688356"],"gpt_icon":0},{"id":"2552468084","title":"7月18日键凯科技涨11.95%,金信价值精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2552468084","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552468084?lang=zh_cn&edition=full","pubTime":"2025-07-18 16:19","pubTimestamp":1752826793,"startTime":"0","endTime":"0","summary":"证券之星消息,7月18日键凯科技涨11.95%创60日新高,收盘报91.8元,换手率6.23%,成交量3.78万手,成交额3.33亿元。重仓键凯科技的公募基金请见下表:该股最近90天内共有3家机构给出评级,买入评级2家,增持评级1家。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为金信基金的金信价值精选混合A。金信价值精选混合A目前规模为0.65亿元,最新净值1.773,较上一交易日上涨2.82%,近一年上涨84.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071800025255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688356","BK0229"],"gpt_icon":0},{"id":"2551903148","title":"键凯科技:凝胶项目已取得生产许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2551903148","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551903148?lang=zh_cn&edition=full","pubTime":"2025-07-16 15:33","pubTimestamp":1752651185,"startTime":"0","endTime":"0","summary":"证券之星消息,键凯科技(688356)07月16日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司的凝胶医美产品收到生产许可证了吗?键凯科技回复:尊敬的投资者您好,感谢您的提问!凝胶项目已取得生产许可证。再次感谢您对键凯科技的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071600019836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","688356"],"gpt_icon":0},{"id":"2551414846","title":"键凯科技:mRNA肿瘤疫苗处于临床前研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2551414846","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551414846?lang=zh_cn&edition=full","pubTime":"2025-07-16 15:33","pubTimestamp":1752651184,"startTime":"0","endTime":"0","summary":"证券之星消息,键凯科技07月16日在投资者关系平台上答复投资者关心的问题。公司与康希诺生物子公司康希诺(上海)生物研发有限公司合作开发的mRNA肿瘤疫苗目前仍处于临床前研究阶段。研究结果表明,ISL-3C-LNP在安全性提高和细胞免疫应答增强方面有显著效果,并具有组分简化与专利优势。该研究发表在国际权威期刊ACSAppliedMaterials&Interfaces上。再次感谢您对键凯科技的关注!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071600019832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","159646","688356"],"gpt_icon":0},{"id":"2551148132","title":"键凯科技:水光针项目目前处于CMDE技术审评阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2551148132","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551148132?lang=zh_cn&edition=full","pubTime":"2025-07-16 15:33","pubTimestamp":1752651183,"startTime":"0","endTime":"0","summary":"证券之星消息,键凯科技(688356)07月16日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司的长效水针,CMDE开始技术审评了吗?键凯科技回复:尊敬的投资者您好,感谢您的提问!公司于2025年5月29日发布“关于自愿披露注射用透明质酸钠复合溶液注册申请获得受理的公告”,水光针项目目前处于CMDE技术审评阶段,具体后续进展情况请您以公司官方披露为准。再次感谢您对键凯科技的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071600019829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688356","BK0229"],"gpt_icon":0},{"id":"2551116584","title":"肿瘤治疗概念盘中拉升,广生堂涨6.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551116584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551116584?lang=zh_cn&edition=full","pubTime":"2025-07-16 09:44","pubTimestamp":1752630253,"startTime":"0","endTime":"0","summary":"07月16日,肿瘤治疗概念盘中拉升,截至09点44分,肿瘤治疗概念整体指数上涨0.53%,报1597.610点。从个股上来看,该概念的成分股中,广生堂涨6.94%,键凯科技涨幅超过5%。从资金上来看,截止发稿,肿瘤治疗概念主力净流入为8114.53万,其中华东医药受到资金热捧,主力净流入3553.98万;拉长时间线来看,该板块近20日主力资金净流入-40.32亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071609441395443306&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071609441395443306&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["300436","BK0239","688356","BK0229"],"gpt_icon":0},{"id":"2551128159","title":"每周股票复盘:XD键凯科(688356)键凯科技2024年年度权益分派实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2551128159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551128159?lang=zh_cn&edition=full","pubTime":"2025-07-13 07:33","pubTimestamp":1752363186,"startTime":"0","endTime":"0","summary":"截至2025年7月11日收盘,XD键凯科报收于73.29元,较上周的72.59元上涨0.96%。本周关注点键凯科技发布2024年年度权益分派实施公告,每10股派发现金红利1.50元(含税)公司公告汇总键凯科技发布2024年年度权益分派实施公告。北京键凯科技股份有限公司董事会2025年7月7日。北京市时代九和律师事务所接受北京键凯科技股份有限公司委托,就公司2024年年度利润分配涉及的差异化权益分派事项出具法律意见书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071300001397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688356","BK0229"],"gpt_icon":0},{"id":"2548286353","title":"键凯科技:公司在小核酸药物方面有部分自研管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2548286353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548286353?lang=zh_cn&edition=full","pubTime":"2025-07-02 15:33","pubTimestamp":1751441629,"startTime":"0","endTime":"0","summary":"证券之星消息,键凯科技07月02日在投资者关系平台上答复投资者关心的问题。公司在小核酸药物方面有部分自研管线,目前仍处于临床前研究阶段。此外,公司支持下游客户的小核酸药物研发项目,目前该类客户均处于临床或早期研发阶段,尚未有已经商业化的产品。再次感谢您对键凯科技的关注!","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070200020095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","688356"],"gpt_icon":0},{"id":"2548322863","title":"键凯科技:丝玫瑰产品使用新型PEG衍生物作为交联剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2548322863","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548322863?lang=zh_cn&edition=full","pubTime":"2025-07-02 15:33","pubTimestamp":1751441618,"startTime":"0","endTime":"0","summary":"证券之星消息,键凯科技07月02日在投资者关系平台上答复投资者关心的问题。该产品使用新型PEG衍生物作为交联剂取代传统交联剂。再次感谢您对键凯科技的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070200020073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688356","BK0229"],"gpt_icon":0},{"id":"2547015164","title":"中国创新药能否持续让世界买单?券商分析师最新观点","url":"https://stock-news.laohu8.com/highlight/detail?id=2547015164","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547015164?lang=zh_cn&edition=full","pubTime":"2025-06-30 23:29","pubTimestamp":1751297340,"startTime":"0","endTime":"0","summary":"医药魔方统计,2025年1—5月,中国创新药企对外授权交易总金额已达455亿美元,超过2024年上半年的交易总额,创新药出海授权交易大爆发。亮眼数据的背后,是中国创新药整体水平的强势崛起。“中国创新药产业的研发、临床与生产能力,正处于与国际一线水平接轨的初始阶段。”由于BD数据不及预期,年内大涨明显的创新药企业荣昌生物股价近期大幅回调,从而带动创新药板块整体调整。华泰柏瑞恒生创新药ETF6月中旬以来一度单周下行超过8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","600513","688163","688166","600216","603127","688068","688319","688202","688073","600535","600196","600682","603259","600521","600572","688317","06160","600420","603456","600645","688177","600422","688189","688506","600276","688235","600867","600380","603716","688356","688520","BK0239","600881","603590","601607","600789","603087","688198","603367","600267","688222","603707","603998","688181","159992","688331","600079","600851","600222","688091","600351","603567","688488","688505","600557","600200","600721","601089","ONC","600080","688336","600332","600774","688131","688278","600998","605199","600062","600056","688136","688513","603229","688117"],"gpt_icon":0},{"id":"2546783037","title":"键凯科技06月26日遭主力抛售211.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546783037","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546783037?lang=zh_cn&edition=full","pubTime":"2025-06-26 15:21","pubTimestamp":1750922501,"startTime":"0","endTime":"0","summary":"06月26日, 键凯科技股价跌0.80%,报收68.00元,成交金额5109.8万元,换手率1.23%,振幅3.40%,量比0.94。键凯科技今日主力资金净流出211.9万元,上一交易日主力净流出180.5万元。该股近5个交易日上涨1.19%,主力资金累计净流出611.3万元;近20日主力资金累计净流出9485.2万元,其中净流出天数为15日。|06月26日主力加仓幅度排名||#|股票简称|主力净额占比|#|欢瑞世纪|6.52%|#|华锋股份|6.02%|#|科创信息|5.98%|#|...|...|#2921|键凯科技|-0.05%|键凯科技所在的化学制药行业,今日主力净流出16.11亿元,行业排名7/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626170316a4bede8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626170316a4bede8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688356","BK0229"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753877841483,"stockEarnings":[{"period":"1week","weight":-0.0292},{"period":"1month","weight":0.4881},{"period":"3month","weight":0.6761},{"period":"6month","weight":1.0572},{"period":"1year","weight":0.9044},{"period":"ytd","weight":0.7956}],"compareEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":0.0542},{"period":"3month","weight":0.1008},{"period":"6month","weight":0.1105},{"period":"1year","weight":0.2482},{"period":"ytd","weight":0.077}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京键凯科技股份有限公司","boardCode":"AI0026","boardName":"化学原料和化学制品制造业","stockholders":"4901人(较上一季度增加3.57%)","perCapita":"12375股","listingDate":"2020-08-26","address":"北京市海淀区西小口路66号中关村东升科技园北领地·C-1楼3层306,308,310,311(东升地区)","registeredCapital":"6065万元","survey":" 北京键凯科技股份有限公司的主营业务是医用药用聚乙二醇及其活性衍生物的研发、生产和销售。公司的主要产品是医用药用聚乙二醇及其活性衍生物。国家级专精特新“小巨人”企业、制造业“单项冠军”。","listedPrice":41.18},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"键凯科技(688356)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供键凯科技(688356)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"键凯科技,688356,键凯科技股票,键凯科技股票老虎,键凯科技股票老虎国际,键凯科技行情,键凯科技股票行情,键凯科技股价,键凯科技股市,键凯科技股票价格,键凯科技股票交易,键凯科技股票购买,键凯科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"键凯科技(688356)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供键凯科技(688356)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}